US Stock MarketDetailed Quotes
ILMN Illumina
- 121.050
- -1.820-1.48%
Close Apr 25 16:00 ET
- 120.010
- -1.040-0.86%
Post 17:24 ET
19.28BMarket Cap-16491P/E (TTM)
122.035High116.910Low962.08KVolume121.970Open122.870Pre Close115.14MTurnover0.61%Turnover RatioLossP/E (Static)159.26MShares213.91052wk High3.36P/B19.22BFloat Cap89.00052wk Low--Dividend TTM158.76MShs Float555.770Historical High--Div YieldTTM4.17%Amplitude0.855Historical Low119.681Avg Price1Lot Size
Illumina Stock Forum
Sign in to post a comment
ColumnsMissed out on Nvidia? These Alternatives Are Expected to See Growth: Goldman Sachs
The landscape of U.S. equities is abuzz with anticipation as artificial intelligence (AI) cements its place as a transformative force in the technology sector. In a recent analysis by $Goldman Sachs(GS.US$, optimism for AI integration remains robust, yet valuations steer clear of the vertiginous heights of previous market bubbles.
Goldman Sachs' insights reveal that market-implied long-term growth expectations hav...
Goldman Sachs' insights reveal that market-implied long-term growth expectations hav...
72
1
Illumina's declining share price indicates market disappointment with its growth. The company's unprofitability and low revenue growth are seen as risky. Poor performance over the past year suggests unresolved challenges, and long-term share price weakness could be a bad sign. However, contrarian investors might see potential for a turnaround.
$Illumina(ILMN.US$ What happened 🤔
Given the liabilities on Illumina's balance sheet, relative to cash, and the company's EBIT loss over the last year, the existence of any debt seems unwise. The lack of profitability and decreasing revenue indicate a risk-averse environment for investors.
Jim Cramer reviews the worst performers on the Nasdaq-100 in 2023
Jim Cramer on Thursday gave his take on the worst performers in the Nasdaq-100 in 2023.
$Moderna(MRNA.US$ : Cramer noted that this pharmaceutical giant was also one of the bottom stocks on the S&P 500 last year, suggesting it may still be suffering from a post-Covid hangover.
$Illumina(ILMN.US$: Cramer likened this diagnostic equipment manufacturer to Moderna, a company that saw success during the pandemic but has since "failed t...
$Moderna(MRNA.US$ : Cramer noted that this pharmaceutical giant was also one of the bottom stocks on the S&P 500 last year, suggesting it may still be suffering from a post-Covid hangover.
$Illumina(ILMN.US$: Cramer likened this diagnostic equipment manufacturer to Moderna, a company that saw success during the pandemic but has since "failed t...
2
Geno stocks really doing well! Don’t miss the bullet train!!! 😍😍😍
$Pacific Biosciences of California(PACB.US$
$CRISPR Therapeutics(CRSP.US$
$Illumina(ILMN.US$
$Pacific Biosciences of California(PACB.US$
$CRISPR Therapeutics(CRSP.US$
$Illumina(ILMN.US$
2
Despite disappointing revenue growth, Illumina's future prospects keep investors hopeful and willing to pay a high P/S ratio. Assuming stable future revenues, the share price isn't expected to drastically fall soon.
Illumina's divestment of the Grail is seen as a move to regain investor confidence, in spite of the loss-making Grail having negatively impacted Illumina's earnings.
2
ColumnsToday's Morning Movers and Top Ratings: X, NIO, LUV, PLD and More
Morning Movers
Gapping up
$Illumina(ILMN.US$ shares rose by 5.33% in premarket trading in New York on Monday, after the gene-sequencing device maker said it will offload cancer screening start-up Grail.
In a statement on Sunday, San Diego-based Illumina noted that divestiture will be executed through a "third-party sale or capital markets transaction" and is expected to be finalized by the end of the second quarter of next year.
$Salesforce(CRM.US$ shares ro...
Gapping up
$Illumina(ILMN.US$ shares rose by 5.33% in premarket trading in New York on Monday, after the gene-sequencing device maker said it will offload cancer screening start-up Grail.
In a statement on Sunday, San Diego-based Illumina noted that divestiture will be executed through a "third-party sale or capital markets transaction" and is expected to be finalized by the end of the second quarter of next year.
$Salesforce(CRM.US$ shares ro...
17
The court's ruling is seen as a 'major win' for the FTC in a vertical merger case. Despite setbacks, Illumina could get another chance to argue their strategy if it continues to battle in court.
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Chen Kiat : Very informative